ACAD Latest Headlines

Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD) and Assembly Biosciences (ASMB)

at www.tipranks.com (Fri, 9-Oct 6:10 AM)

ACAD Slides as Remlifanserin Misses Primary Endpoint (p=0.0603) Despite Nominal Win on CGI-S-ADP

Market Chameleon (Thu, 24-Sep 11:48 AM)

ACAD advances remlifanserin into refined Phase 3 plan after 60 mg dose showed a widening week-6 separation vs placebo

Market Chameleon (Thu, 24-Sep 7:30 AM)

Acadia Pharmaceuticals Raises Full-Year Outlook on Robust DAYBUE and NUPLAZID Sales Surge

Market Chameleon (Wed, 5-Aug 11:11 AM)

FDA Fast Track Designation for Remlifanserin Highlights Acadia’s Progress in Alzheimer’s Disease Psychosis

Market Chameleon (Mon, 20-Jul 9:39 AM)